<DOC>
	<DOCNO>NCT02682225</DOCNO>
	<brief_summary>The primary objective study evaluate abuse potential intranasal esketamine ( 112 milligram 84 mg ) compare racemic intravenous ketamine ( 0.5 mg/kg ) nondependent , recreational polydrug user perception-altering drug .</brief_summary>
	<brief_title>Crossover Study Evaluate Abuse Potential Intranasal Esketamine Compared Racemic Intravenous Ketamine Nondependent , Recreational Drug Users</brief_title>
	<detailed_description>This single-center , single-dose , double-blind , double-dummy , placebo-controlled ( participant randomly assign test treatment identical-appearing treatment contain test drug ) , randomize ( study medication assign participant chance ) , crossover study 120 men woman self-identifying current , recreational , nondependent polydrug user . The study Screening Phase ( consist Screening Visit Qualification Session ) Treatment Phase . In Qualification Session participant randomize receive Sequence 1 : intravenous placebo intranasal placebo concurrently ( Treatment A ) Day 1 intravenous dose ( 0.5 mg/kg ) racemic ketamine intranasal placebo concurrently ( Treatment B ) Day 2 , participant receive Sequence 2 : Treatment B Day 1 Treatment A Day 2 . In Treatment Phase eligible participant administer 4 treatment : A , B , C ( intravenous placebo intranasal 84 mg esketamine 3 device , 28 mg esketamine follow 1 device placebo ) D ( intravenous placebo intranasal 112 mg esketamine 4 device , 28 mg esketamine ) cross-over manner ( 1 treatment per period ) Sequence 3 , 4 , 5 , 6 . Periods 1 , 2 , 3 , 4 separate 7 14 day . Primarily drug abuse potential evaluate . Safety participant monitor throughout study .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Participants body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight less 50 kg Signed informed consent document indicate understand purpose procedure require study willing participate study , include pharmacogenomic research component study Be current , recreational , nondependent , polydrug user define nonmedical use least 2 type perceptionaltering drug abuse ( example , lysergic acid diethylamide , cannabinoids , ketamine , ecstasy/3,4methylenedioxymethamphetamine , phencyclidine , psilocybin , ringsubstituted amphetamine perception alter effect ) least 10 total lifetime occasion use perceptionaltering drug abuse like effect Report use ketamine least lifetime without moderate severe adverse effect Report use perceptionaltering drug ( example , lysergic acid diethylamide , cannabinoids , ketamine , ecstasy/3,4methylenedioxymethamphetamine , phencyclidine , psilocybin , ring substitute amphetamine perception alter effect ) least within 3 month prior screen phase without moderate severe adverse effect Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic disease , infection , hypertension vascular disorder , kidney urinary tract disturbance , sleep apnea , myasthenia gravis , illness investigator considers exclude participant could interfere interpretation study result Participant current prior diagnosis psychotic bipolar disorder Participant clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center ( Day 1 Qualification Session period Treatment Phase ) determine investigator Participant history presence drug ( exclude nicotine caffeine ) alcohol dependence accord 4th edition Diagnostic Statistical Manual Mental Disorders ( DSMIV ) criteria Participation treatment substancerelated disorder within 3 year prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Esketamine</keyword>
	<keyword>Placebo</keyword>
	<keyword>Racemic ketamine</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>